TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...

Methotrexate is a generic drug prescribed to treat certain types of cancers, arthritis, and psoriasis in adults and some children. As with other drugs, methotrexate can cause side effects, such as ...

The US Food and Drug Administration (FDA) has approved a subcutaneous injectable methotrexate delivered in an auto-injector (Rasuvo, Medac Pharma) for rheumatoid arthritis (RA), polyarticular-course ...

Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the ...

Methotrexate comes as an injection given under your skin or into your muscle. It also comes as a tablet you swallow and an intravenous (IV) infusion (an injection into your vein given over time). But ...

Methotrexate falls into the category of disease-modifying antirheumatic drugs, or DMARDs. These drugs do more than deal with symptoms; they actually slow down progression of the disease. About 60 ...

The FDA approved pegloticase (Krystexxa) injection coadministered with methotrexate, Horizon Therapeutics announced Friday. Pegloticase is currently the only FDA-approved medication used to reduce ...

If you’re looking at treatment options for psoriasis, arthritis, or certain kinds of cancer, you may want to learn more about methotrexate. For more details on methotrexate’s uses and more, see this ...

TORONTO--(BUSINESS WIRE)--NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet ® for the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A retrospective analysis of methotrexate ...

TOKYO, May 22, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent“Metoject® Subcutaneous ...